Sage Journals: Discover world-class research

Abstract

MicroRNAs are non-coding RNA sequences that act as regulators of gene expression. They are aberrantly expressed in many pathological conditions. Cardiovascular diseases are among the leading causes of morbidity and mortality in the general population. Various knock-in and knockdown approaches have shown abnormal signature patterns of microRNAs in cardiovascular conditions like cardiac hypertrophy, myocardial infarction, heart failure, arrhythmias and vascular proliferative diseases. Since a single microRNA targets many genes, modulating a single microRNA involved in a disease carries a possible risk of undesirable side effects. The review focuses on current understanding of microRNAs in cardiovascular conditions, the possible underlying mechanisms and various approaches of modulating microRNAs.

Keywords

MicroRNAs gene regulation cardiovascular diseases

Introduction

MicroRNAs (miRNAs) are an abundant class of small non-coding entities discovered first in Caenorhabditis elegans when the product of lin-4 gene was found to suppress lin-14 gene expression.¹ They provide a ubiquitous and powerful mechanism for RNA-mediated control of gene expression.² A total of 7000 miRNAs are defined by now, which impact the understanding of information encoded by genomic sequences and transcribed units. About 1872 precursors and 2578 mature human miRNAs have been reported in human genome as per current version of miRBase. (http://www.mirbase.org).³ miRNAs affect gene expression at multiple levels including pre-transcriptional, transcriptional and post-transcriptional.⁴ The extent of genome regulation by miRNAs is controversial, with some reports suggesting more than 70% of the human genome being regulated by miRNAs,⁵ while others report a number close to 30%.⁶ Each miRNA has multiple targets inside a cell, and similarly, each gene is targeted by multiple miRNAs. Recently, miRNAs have been implicated in the pathogenesis of a spectrum of diseases and are believed to serve as important functional targets of the future.

Synthesis of miRNAs

miRNAs are synthesized as primary miRNA (pri-miRNA) with a hairpin structure from non-coding region of DNA by RNA polymerase II.⁷ pri-miRNA is then acted upon by DGCR8/ Pasha and Drosha (RNAase III) to form 70-to-80-nucleotides-long precursor miRNA (pre-miRNA), which is exported out of the nucleus into the cytoplasm using Exportin. In the cytoplasm, pre-miRNA is targeted by another RNAase III, Dicer and trans-activation response (TAR) RNA binding protein (TRBP) to form miRNA. The immature miRNA then associates with Ago-proteins to form mature RNA-induced silencing complex (RISC). RISC binds to the 3′-untranslated region (3′UTR) of target messenger RNA (mRNA) by a ‘seed region’ composed of six to seven nucleotides. Mature RISC causes degradation of mRNA if the binding sequence shows a perfect complementarity with mRNA. It can suppress translation if there is imperfect binding between mRNA and miRNA.⁸ Figure 1 shows biogenesis of miRNA.

Figure 1.

Biogenesis of miRNA.

miRNAs can be transcribed independently as single transcription units (e.g. micro RNA(miR)-143)⁹ or together with genes in which they are located (e.g. miR-126).¹⁰ Furthermore, miRNAs may also be derived directly from introns when they are known as mirtrons.¹¹ Proteins produced by mRNAs that are targets of miRNA can also regulate the expression of many miRNAs adding complexity to miRNA-induced gene regulation.^12,13 miRNAs regulate transcription factors, which in turn regulate the expression of miRNA forming a double negative feedback. For example, p53, which is a target of multiple miRNAs, regulates miR-143.¹⁴ Similarly, SMAD, a signal transducer of transforming growth factor–beta (TGF-β), regulates miR-21 and miR-199a.¹⁵ Furthermore, many miRNAs are subjected to regulation by methylation patterns governed by epigenetic mechanisms, which are determined by environmental and other pathophysiological states.¹⁶

miRNAs and cardiac hypertrophy

Cardiac hypertrophy is a major compensatory cellular response of the heart to stressful conditions such as ischemia, injury, metabolic alterations, hypertension or genetic abnormalities. The pathological hypertrophy in fact acts as a major predictor of sudden cardiac death, heart failure and arrhythmias. It involves altered expression profile of certain miRNAs with a shift to the fetal gene program. There is a change in intracellular signaling pathways leading to increased protein synthesis and enhanced deposition of extracellular matrix proteins.¹⁷ miRNAs upregulated in cardiac hypertrophy include miR-21, miR-23a, miR-23b, miR-24, miR-208, miR-212, miR-125, miR-129, miR-195 and miR-199, while those downregulated are miR-1, miR-133, miR-29, miR-30 and miR-150.^18–20

One miRNA which is consistently linked with stress and functions to regulate cardiac growth is miR-21. miR-21 is involved in the pathogenesis of many cancers too and is termed as oncomiR.²¹ It is highly expressed in cardiomyocytes²² and fibroblasts.²³ miR-21 inhibition in cultured cardiac cells suppresses cardiomyocyte growth and can also block β-adrenergic receptor–mediated cardiomyocyte growth.²⁴ The in vivo effect of miR-21 on cardiomyocytes was shown in a study where downregulation of miR-21 was found to reduce the heart size. miR-21 targets the ‘sprouty gene’—SPRY1—and represses its function resulting in overexpression of mitogen-activated protein kinase (MAPK/ERK) and consequently causing fibrosis. Other genes targeted by miR-21 include programmed cell death gene (PDCD4) and phosphatase and tensin homolog deleted on chromosome 10 (PTEN).²⁵ Another miRNA which is upregulated in rodent and human hearts in hypertrophic conditions is miR-195. Forced expression of miR-195 has been found to induce hypertrophic growth.¹⁸

miR-208 contributes to stress-induced cardiac hypertrophy by regulating triiodothyronine-dependent repression of β-myosin heavy chain (β-MHC).^26,27 It targets thyroid hormone receptor–associated protein and derepresses β-MHC resulting in hypertrophy of myocytes. miR-208 indeed works cooperatively with stress signaling to modulate gene expression. Targeting miR-208 with a locked nucleic acid (LNA)-based antagomir (antagonist of miRNA) has been recently shown to prevent functional deterioration and improve survival in patients with heart failure.²⁸

miR-23 is a pro-hypertrophic miRNA, activated by nuclear factor of activated T-cells (NFAT).²⁹ miR-23 then targets muscle-specific ring finger protein which is thought to be cardio-protective.²⁹ Thus, miR-23 can be considered as a useful target in cardiac hypertrophy. More recently, miR-22 overexpression has been linked to hypertrophic pathways. miR-22 functions as an integrator of Ca²⁺ hemostasis during stress and as a regulator of protein content of myofibres.³⁰ miR-22 is believed to promote hypertrophy by suppressing PTEN, thereby stimulating phosphoinositide-3 kinase/Akt (PI₃K/Akt)pathway.³¹ miR-22 expression–mediated hypertrophic changes have been recently shown to be modulated by the hypolipidemic drug Atorvastatin suggesting a novel role of pharmacological interventions in cardiac hypertrophy.³²

In contrast to the above miRNAs, which have a stimulatory role in cardiac hypertrophy, downregulation of miR-133 and miR-1 manifests in cardiac hypertrophy. Significant hypertrophy was induced in mice after knockdown of miR-133 using antisense oligonucleotides, while overexpression of miR-133 by adenovirus-mediated transfer-inhibited cardiomyocyte hypertrophy. miR-133 targets RhoA and Cdc42 as a basis to suppress hypertrophy.³³ It also targets connective tissue growth factor (CTGF), and thereby inhibits extracellular matrix protein synthesis.³⁴ miR-1 targets hypertrophy-associated calmodulin and attenuates calcineurin–NFAT pathway involved in signaling hypertrophy.³⁵ miR-133 and miR-1 seem to be cardio-protective and may be targeted as a promising therapeutic strategy.

Other miRNAs which are downregulated in various models of hypertrophy and heart failure are miR-29 and miR-9. miR-29 targets elastin, fibrillin and collagen. Therefore, derepression of these proteins in ‘miR-29 downregulation’ opens up events leading to cardiac fibrosis. In vivo administration of cholesterol-based oligonucleotides against miR-29 has shown increased collagen expression and fibrotic changes.³⁶ miR-9 is downregulated in animal models of hypertrophy induced by aldosterone and isoproterenol, while nuclear factor of activated T-cells c3 (NFATc3) and myocardin appear to be overexpressed. Administration of miR-9 carries the potential to suppress myocardin expression and hence to regulate the hypertrophic program.³⁷

Understanding the molecular mechanisms behind the pathological hypertrophy of the heart and finding out novel therapeutic targets is evolving as a field of immense interest.

Arrythmias and miRNAs

Normal conduction in the heart requires a proper functioning of various ion channels. Na⁺ influx leads to membrane depolarization, while K⁺ efflux results in repolarization. A protein Connexin 43(Cx43) is essential for conduction across gap junctions.^38,39 L-type Ca²⁺ channels determine the shape of the action potential by facilitating excitation–contraction coupling. miR-1 targets GJAI coding for Cx43⁴⁰ and KCNJ2 coding for Kir2.1.^41,42 miR-1 is increased in coronary artery disease and results in slowing up of conduction and arrhythmias. Blocking miR-1 with antisense oligonucleotides has been shown to normalize conduction and attenuate the arrhythmias seen in myocardial infarction (MI). This is complicated by the results of another study which showed increased ventricular septal defects in mice with targeted deletion of miR-1-2 owing to derepression of Irx5 transcription factor.⁴³ Inward rectifier potassium current–mediated repolarization is also affected by miR-133 which represses hERG (human ether-a-go-go-related gene).⁴⁴ miR-133 also targets HCN2 gene involved in automaticity.⁴⁵ miR-1 and miR-133 may serve as targets in the management of arrhythmias.

MI and miRNAs

Oxidative stress and myocyte apoptosis are the key factors involved in the pathogenesis of ischemic heart disease. Angiogenesis and myocardial preconditioning serve as cardio-protective mechanisms in this setting. miRNAs involved in angiogenesis and ischemic preconditioning are potentially of therapeutic use in MI. Various miRNAs implicated in ischemic heart disease include miR-1, miR-133, miR-19, miR-21, miR-199 and miR-320. miR-320 has been found to be consistently overexpressed in the ischemic heart in a mouse model of ischemia reperfusion–mediated injury. It targets cardio-protective heat shock protein–20 (hsp 20) and contributes to myocyte death.⁴⁶ Furthermore, miR-21 is found to be downregulated in infarcted areas, and adenovirus-mediated expression of miR-21 leads to an attenuated rate of myocyte apoptosis by repression of PDCD4.⁴⁷ miR-21 may also provide cardio-protection via upregulation of hsp 70.⁴⁸

miR-199 acts as a molecular switch when the oxygen tension in myocytes falls in short supply. It targets the protective mediators—hypoxia inducible factor–1α (HIF-1α) and sirtuins—involved in ischemic preconditioning. It can be utilized in preventing hypoxic damage to the heart.⁴⁹ miR-92a targets pro-angiogenic α-5 integrin and inhibits angiogenesis. Antagomirs designed against miR-92a resulted in improved blood vessel growth and reduced functional deterioration of heart tissue.⁵⁰

miR-22 which has already been discussed as a promoter of myocardial hypertrophy has been found to be protective against ischemia reperfusion–mediated injury. miR-22 targets adenosine 3′5′ cyclic monophosphate response element binding protein (CREB)-binding protein (CBP) and functions via anti-apoptotic mechanisms. Adenovirus-mediated transfer of miR-22 in animals has shown a reduction in infarct size, cardiomyocyte apoptosis and decline in creatine kinase levels.⁵¹

Contrastingly, a miRNA which plays a detrimental role in cardiac remodeling is miR-34. It has been seen to be elevated under conditions of pressure overload and silencing of miR-34 and, with suitable interventions, attenuates cardiac remodeling and improves systolic function in animals.⁵² Apart from serving as potential therapeutic targets, miRNAs have the potential to be used as biomarkers of infarction, being present as microparticles in the circulation.^53,54

Metabolic syndrome, cholesterol regulation and miRNAs

miR-33 is involved in cholesterol metabolism. miR-33b is co-expressed with SREBP1, and miR-33a is co-expressed with SREBP2.⁵⁵ miR-33 regulates ABCA1 and reverse cholesterol transport. Antagomirs against miR-33b have shown increase in high-density lipoprotein (HDL) levels and reduction in the size of plaques in mice deficient in low-density lipoprotein (LDL) receptors.^56,57 On the other hand, overexpression of miR-33b is linked with decreased functioning of ABCA1 and hence reduction in HDL levels. Thus, downregulation of miR-33 may be protective in atherosclerosis.

Vascular disease and miRNAs

Vascular proliferation

Vascular injury is a fundamental event in the pathogenesis of coronary artery disease, atherosclerosis and restenosis post-angioplasty. Multiple miRNAs are overexpressed in vascular diseases. miR-21 upregulation is linked with increased proliferation of vascular smooth muscle cells, fibroblasts and endothelial cells. PTEN and PDCD4 are believed to be the normal targets of miR-21. Knockdown of miR-21 has been shown to inhibit vascular injury, and therefore, miR-21 can be targeted for modulating the progress in vascular disease.⁵⁸ Furthermore, miR-221 and miR-222 are also upregulated in injured carotid arteries. P27 (Kip1) and P57 (Kip2) are the major targets of miR-221 and miR-222. miR-221 and miR-222 downregulation may serve as a useful strategy in vascular proliferative disease.⁵⁹

Inflammation

Inflammation and endothelial dysfunction are major determinants of initiation and progression of coronary artery disease. Various factors contributing to endothelial dysfunction include increased LDL, raised blood glucose, obesity, smoking and reactive oxygen species.⁶⁰ Normal endothelium does not express any adhesion molecules, but once activated, there is an increased expression of P and E selectins and vascular cell adhesion molecule–1 (VCAM-1), resulting in enhanced recruitment of leucocytes. Some miRNAs are present in endothelial cell and regulate the inflammatory status. miR-126 expressed in endothelial cell inhibits the activation of VCAM-1. Downregulation of miR-126 is linked to increased tumor necrosis factor–α (TNF-α)–mediated VCAM-1 expression.⁶¹ miR-126 is in fact the first miRNA found to be associated with vascular inflammation. It is regulated by transcription factors Ets-1 and Ets-2.⁶² Ets-1 can be induced by multiple stimuli like angiotensin II (Ang II)⁶³ and TNF-α.⁶⁴ miR-126 supplementation has been shown to provide atheroprotection which is thought to be because of CXCL12-mediated recruitment of progenitor cells.⁶⁵ Ang II is known to provoke vascular injury and cardiac remodeling acting via angiotensin 1 receptors (AT1R). miR-155 targets and inhibits AT1R expression as demonstrated in in vivo studies.⁶⁶ miR-155 further downregulates Ang II-mediated expression of VCAM-1 and monocyte chemotactic protein (MCP-1).⁶⁷ miR-155 seems to be protective in endothelial dysfunction and inflammation induced by Ang II.

Apart from the Ang II pathway, another pathway of note in inflammation-mediated vascular injury is nuclear factor kappa-beta (NF-κβ) signaling. Various inflammatory stimuli—LDL, lipopolysaccharides and cytokines—appear to induce the expression of inflammatory genes through NF-κβ. This results in upregulation of P-selectins, intercellular adhesion molecule–1 (ICAM-1) and VCAM-1.⁶⁸ miR-10a is protective against the NF-κβ pathway as downregulation of miR-10a is linked with increased expression of interleukin-6 (IL-6), IL-8 and VCAM-1.⁶⁹ Another miRNA believed to interfere with NF-κβ functioning is miR-181-b. miR-181-b targets importin-a3, a protein required for nuclear translocation of NF-κβ. miR-181-b levels are reduced in mice exposed to inflammatory stimuli and in patients with sepsis. miR-181-b replacement seems to protect against NF-κβ-mediated vascular injury.⁷⁰

Angiogenesis

Angiogenesis is a major determinant of cardiac repair following MI. Vascularization depends on growth factors like vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).⁷¹ Various aspects of blood vessel growth are modulated by miRNAs. miR-126 promotes vascularization by targeting Spred-1, which is an inhibitor of MAPK involved in downstream signaling of VEGF.⁷² Upregulation of miR-126 therefore frees VEGF signaling from being suppressed by Spred-1. miR-126 is also involved in migration of hematopoietic stem cells to the sites of cardiac injury.⁷³ Other miRNAs that influence blood supply include miRNA-221 and miRNA-222. miR-221 and miR-222 inhibit angiogenesis by targeting c-kit and by decreasing endothelial nitric oxide synthase (eNOS) expression.^74,75

Heart failure and miRNAs

Majority of studies relating miRNAs and heart disease have been conducted on heart failure. Heart failure is a situation when cardiac output is unable to meet the demands of tissues. Since hypertrophy, arrhythmias and vascular disease discussed above can lead to heart failure, it would not be wrong to say that miRNAs implicated in these pathological conditions may also be involved in heart failure. Notably, the miRNAs upregulated include miR-21, miR-129 and miR-210, while those downregulated include miR-30 and miR-182.³⁵ As in hypertrophy, there is a shift toward fetal gene programming in heart failure too. Various miRNAs are expressed in a similar way in adult failing heart as in the fetal heart.²⁴ This change toward fetal gene expression may contribute to pathological features seen in heart failure. Understanding the miRNA profile expressed in failing heart may give us an opportunity to validate the targets selectively.

Preeclampsia and miRNAs

Preeclampsia acts as a risk factor for cardiovascular disease in women.⁷⁶ It also increases the risk that a child born to a mother with the condition would suffer a stroke in adulthood.⁷⁷ Results of four surveys conducted recently on miRNA expression in preeclamptic mothers show a total of 67 human miRNAs to be differently regulated.⁷⁸ These include miR-181a, miR-195, miR-584, miR-155, miR-222 and miR-210. miR-210 is induced in response to hypoxia.⁷⁹ Recently, some miRNAs have been detected in the plasma of preeclamptic mothers. These include miR-144, miR-181a and miR-130a.⁸⁰ A rich source of these miRNAs is the placenta.⁸¹ Detection of miRNA molecular markers at an early stage may aid in diagnosing as well as prove useful in understanding the pathogenesis of preeclampsia.

Endothelial dysfunction and miRNAs

As has been discussed, endothelial dysfunction has a pivotal role in atherosclerosis and coronary heart disease. The involvement of miR-126 and miR-155 in the same has been highlighted.^61–66 miR-34 and miR-217 bring about endothelial senescence by suppressing sirtuin-1 (SIRT1), which is normally required for endothelial proliferation.⁸² miR-10a inhibits endothelial inflammation by suppressing NF-κβ signaling pathway.⁸²

Folic acid in high dose has been shown to improve endothelial function in various studies.^83,84 The mechanisms of folate action which have been proposed include increasing the bioavailability of tetrahydrobiopterin (BH₄), enhancing the coupling of BH₄ with eNOS, favoring the generation of active forms of BH₄ from inactive BH₂ and assuring the direct activation of eNOS independent of BH₄.⁸⁵ miRNAs may be intricately linked to the functioning of folate. Both are associated with aberrant phenotypes ranging from neural tube defects to tumor genesis. Misexpression of various miRNAs has been demonstrated in neural tube defects resulting from folate deficiency.⁸⁶ Folate deficiency state is also linked with many cancers,⁸⁷ and recently, altered expression of miRNAs has been shown under conditions of cellular stress in vitro.⁸⁸ Taking this into consideration, the improvement in endothelial function after folate supplementation in diabetes and coronary artery disease may also be linked to the modulation of miRNAs. Adding to this, obesity-linked hormones such as leptin are also subject to transcriptional regulation.⁸⁹ Table 1 shows the involvement of various miRNAs in heart disease.

Table 1.

Involvement of various microRNAs (miRNAs) in cardiovascular disease.

Condition	miRNAs involved
Cardiac hypertrophy	miR-21,²⁴ miR-22,³¹ miR-23,²⁹ miR-1,³⁵ miR-29³⁶
Arrythmias	miR-1,⁴³ miR-133⁴⁴
Myocardial infarction	miR-320,⁴⁶ miR-22,⁵¹ miR-21⁴⁷
Vascular disease	miR-21,⁵⁸ miR-222,⁵⁹ miR-126,⁶¹ miR-155⁶⁷
Angiogenesis	miR-126,⁷² miR-92⁵⁰
Cholesterol metabolism	miR-33^56,57
Endothelial dysfunction and inflammation	miR-126,^61,62 miR-10,⁸² miR-155⁶⁶

miRNA-based therapies

Antagomirs

Antagomirs are a sequence of antisense oligonucleotides designed to act against the targeted miRNA involved in disease pathology. They may act either by competing with miRNA and inhibiting the RISC function or may interfere with the processing of primary miRNA.⁹⁰ Suppression of miRNA results in derepression of protein by inhibiting the degradation of concerned mRNA or preventing the translational suppression by miRNA. As discussed above, antagomirs against miR-208 and miR-21 have given useful results.^25,28 To increase the binding affinity of antagomirs to their target miRNA, certain modifications like 2′-O-methyl and 2′-O-methoxy ethyl are introduced to the oligonucleotides. Further addition of phosphorothioate groups leads to the formation of tiny LNAs, which adds to the biostability and increases delivery to the tissues as well. Tiny LNAs may be well suited for inhibition of disease-specific miRNAs.⁹¹ However, there are some shortcomings of this antisense technique. Being polyanionic, they are not suitable for oral use. Only routes used currently are intravenous and subcutaneous.⁹⁰ In addition, there are problems because of poor cellular uptake and degradation by nucleases in plasma. Further concern is of toxicity. Toxicities may arise because of the chemical nature of antagomirs as in case of phosphorothioate oligonucleotides, which can activate the innate immunity⁹² and complement cascade.⁹³ Toxicity may also arise because of hybridization with and inactivation of unintended target RNA resulting in off-target side effects. These effects can be minimized by stringent selection of sequences.⁹⁰

miRNA mimics

These are synthetic miRNAs which are useful in miRNA-deficient conditions.⁹⁴ Using a suitable viral vector, they can be continually expressed to circumvent the problem of miRNA downregulation in underlying disease. Short double-stranded RNA sequences are used for loading into RISC. Problem of off-target side effects is unlikely in this approach since only miRNA of interest with sequence same as that of natural miRNA is delivered. As discussed above, miR-1, miR-133 and miR-29 upregulation may be a useful strategy in the management of cardiac hypertrophy and heart failure.^33–36 The field of miRNA mimics is still in the period of basic research.

Several other approaches recently studied include miRNA sponges, miRNA erasers and miRNA occupiers. miRNA sponges consist of a series of oligonucleotides in the 3′UTR of a reporter gene, which have a perfect or imperfect binding site for the target miRNA. Thus, all members of a miRNA family are inhibited by miRNA sponges.⁹⁵ miRNA erasers are similar to miRNA sponges except that they are composed of only two copies of antisense sequence with a perfect binding to target miRNA. miRNA occupiers rather bind directly to 3′UTR of mRNA and inhibit the binding of miRNA to mRNA. Occupiers, therefore, carry the advantage of minimizing the off-target effects.^94,96 In vivo efficacies of these approaches are yet to be discovered.

Conclusion

miRNAs represent important entities which serve as diagnostic and prognostic markers in a variety of diseases as well as bear therapeutic interest. The role of miRNAs in cardiovascular and other conditions is being deciphered with ongoing research. Various miRNAs have been implicated in cardiovascular diseases, and targeting these miRNAs has already given useful results in experimental studies. The area needs more investigation related to the underlying mechanisms as more and more miRNAs are discovered. In days to come, technologic advances may facilitate pharmacodynamic understanding and pharmacokinetic maneuvering to make medical implications a sound reality. Clinical trials in humans employing the use of antagomirs have already begun, and the field of cardiovascular disease is hopefully the next to be targeted.

Footnotes

Acknowledgements

This study was reported from the Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi, Uttar Pradesh, India.

Declaration of conflicting interests

There is no conflict of interest on the part of any author.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References

Wightman

Ruvkun

. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855–862.

Ambros

. MicroRNAs: tiny regulators with great potential. Cell 2001; 107: 823–826.

Kozomara

Griffiths-Jones

. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014; 42: D68–D73.

Tanzer

Riester

Hertel

. Evolutionary genomics of microRNAs and their relatives. In: Caetano-Anolles

(ed.) Evolutionary genomics and systems biology. Hoboken, NJ: John Wiley & Sons, Inc., 2010, pp. 1–35.

Miranda

Huynh

Tay

. A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126(6): 1203–1217.

Lewis

Burge

Bartel

. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120(1): 15–20.

Ul Hussain

. Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action. Cell Tissue Res 2012; 349(2): 405–413.

Tang

. siRNA and miRNA: an insight into RISCs. Trends Biochem Sci 2005; 30: 106–114.

Cordes

Sheehy

White

. miR-145 and miR-143 regulate smooth muscle cell fate decisions. Nature 2009; 460(7256): 705–710.

10.

Nikolic

Plate

Schmidt

. EGFL7 meets miR-126: an angiogenesis alliance. J Angiogenes Res 2010; 2: 9.

11.

Ruby

Jan

Bartel

. Intronic microRNA precursors that bypass Drosha processing. Nature 2007; 448: 83–86.

12.

Bartel

. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.

13.

Filipowicz

Bhattacharyya

Sonenberg

. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102–114.

14.

Suzuki

Yamagata

Sugimoto

. Modulation of microRNA processing by p53. Nature 2009; 460: 529–533.

15.

Davis

Hilyard

Lagna

. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008; 454: 56–61.

16.

Sato

Tsuchiya

Meltzer

. MicroRNAs and epigenetics. FEBS J 2011; 278: 1598–1609.

17.

McKinsey

Olson

. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115: 538–546.

18.

Van Rooij

Sutherland

Liu

. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255–18260.

19.

Sayed

Hong

Chen

. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100: 416–424.

20.

Sucharov

Bristow

Port

. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008; 45: 185–192.

21.

Tong

Nemunaitis

. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008; 15: 341–355.

22.

Cheng

Yue

. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170: 1831–1840.

23.

Roy

Khanna

Hussain

. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009; 82(1): 21–29.

24.

Thum

Galuppo

Wolf

. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007; 116(3): 258–267.

25.

Thum

Gross

Fiedler

. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980–984.

26.

Van Rooij

Sutherland

. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575–579.

27.

Callis

Pandya

Seok

. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009; 119: 2772–2786.

28.

Montgomery

Hullinger

Semus

. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 14: 1537–1547.

29.

Lin

Murtaza

Wang

. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A 2009; 106: 12103–12108.

30.

Gurha

Abreu-Goodger

Wang

. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 2012; 125: 2751–2761.

31.

Song

. Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J Cell Physiol 2012; 227: 1391–1398.

32.

Wan

. MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention. Cell Physiol Biochem 2013; 31: 997–1008.

33.

Care

Catalucci

Felicetti

. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613–618.

34.

Duisters

Tijsen

Schroen

. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104: 170–178.

35.

Ikeda

Kong

. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009; 29: 2193–2204.

36.

Van Rooij

Sutherland

Thatcher

. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027–13032.

37.

Wang

Long

Zhou

. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 2010; 285(16): 11903–11912.

38.

Jongsma

. Diversity of gap junctional proteins: does it play a role in cardiac excitation? J Cardiovasc Electrophysiol 2000; 11: 228–230.

39.

Saffitz

Laing

Yamada

. Connexin expression and turnover: implications for cardiac excitability. Circ Res 2000; 86: 723–728.

40.

Yang

Lin

Xiao

. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13: 486–491.

41.

Diaz

Zobel

Cho

. Selective inhibition of inward rectifier K+ channels (Kir2.1 or Kir2.2) abolishes protection by ischemic preconditioning in rabbit ventricular cardiomyocytes. Circ Res 2004; 95: 325–332.

42.

Wang

Yue

White

. Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 2004; 98: 2422–2428.

43.

Zhao

Ransom

. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129: 303–317.

44.

Xiao

Luo

Lin

. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 2007; 282: 12363–12367.

45.

Luo

Lin

Pan

. Downregulation of MIRNA-1/MIRNA-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 2008; 283: 20045–20052.

46.

Ren

Wang

. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009; 119: 2357–2366.

47.

Dong

Cheng

Yang

. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284: 29514–29525.

48.

Yin

Salloum

Kukreja

. A novel role of microRNA in late preconditioning: upregulation of endothelial nitric oxide synthase and heat shock protein 70. Circ Res 2009; 104(5): 572–575.

49.

Rane

Sayed

. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2007; 104: 879–886.

50.

Bonauer

Carmona

Iwasaki

. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324: 1710–1713.

51.

Yang

Chen

Yang

. MicroRNA-22 targeting CBP protects against myocardial ischemia-reperfusion injury through anti-apoptosis in rats. Mol Biol Rep 2014; 41(1): 555–561.

52.

Bernardo

Gao

Winbanks

. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc Natl Acad Sci U S A 2012; 109(43): 17615–17620.

53.

D’Alessandra

Devanna

Limana

. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765–2773.

54.

Cheng

Tan

Yang

. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010; 119: 87–95.

55.

Najafi-Shoushtari

Kristo

. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566–1569.

56.

Marquart

Allen

Ory

. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A 2010; 107: 12228–12232.

57.

Rayner

Sheedy

Esau

. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921–2931.

58.

Cheng

Yue

. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 2007; 100(11): 1579–1588.

59.

Liu

Cheng

Zhang

. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009; 104: 476–487.

60.

Hadi

Carr

Suwaidi

. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1(3): 183–198.

61.

Harris

Yamakuchi

Ferlito

. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105(5): 1516–1521.

62.

Harris

Yamakuchi

Kondo

. Ets-1 and Ets-2 regulate the expression of microRNA-126 in endothelial cells. Arterioscler Thromb Vasc Biol 2010; 30(10): 1990–1997.

63.

Zhan

Brown

Maynard

. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 2005; 115(9): 2508–2516.

64.

Goetze

Kintscher

Kaneshiro

. TNFalpha induces expression of transcription factors c-fos, Egr-1, and Ets-1 in vascular lesions through extracellular signal-regulated kinases 1/2. Atherosclerosis 2001; 159(1): 93–101.

65.

Zernecke

Bidzhekov

Noels

. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2(100): ra81.

66.

Martin

Lee

Buckenberger

. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 2006; 281(27): 18277–18284.

67.

Zhu

Zhang

Chen

. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration. Atherosclerosis 2011; 215(2): 286–293.

68.

De Winther

Kanters

Kraal

. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005; 25(5): 904–914.

69.

Fang

Shi

Manduchi

. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 2010; 107(30): 13450–13455.

70.

Sun

Icli

Wara

. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest 2012; 122(6): 1973–1990.

71.

Syed

Sanborn

Rosengart

. Therapeutic angiogenesis: a biologic bypass. Cardiology 2004; 101: 131–143.

72.

Fish

Santoro

Morton

. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272–284.

73.

Kocher

Schuster

Szabolcs

. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430–436.

74.

Poliseno

Tuccoli

Mariani

. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108(9): 3068–3307.

75.

Suarez

Fernandez-Hernando

Pober

. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007; 100(8): 1164–1173.

76.

Garovic

Hayman

. Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 2007; 3(11): 613–622.

77.

Kajantie

Eriksson

Osmond

. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke 2009; 40(4): 1176–1180.

78.

Devor

Santillan

. Preeclampsia and microRNAs. Proc Obstet Gynecol 2013; 3(1): article 2 (10 pp.).

79.

Chan

Banerjee

Choi

. miR-210: the master hypoxamir. Microcirculation 2012; 19(3): 215–223.

80.

Zhou

Lin

. Circulating microRNAs are elevated in plasma from severe preeclamptic pregnancies. Reproduction 2012; 143(3): 389–397.

81.

Mincheva-Nilsson

Baranov

. The role of placental exosomes in reproduction. Am J Reprod Immunol 2010; 63(6): 520–533.

82.

Qin

Yang

Xiao

. Role of microRNAs in endothelial inflammation and senescence. Mol Biol Rep 2012; 39: 4509–4518.

83.

Doshi

McDowell

IFW

Moat

. Folic acid improves endothelial function in coronary artery disease patients via mechanisms largely independent of homocysteine lowering. Circulation 2002; 105: 22–26.

84.

Kaur

Pandey

. Role of folate in management of endothelial dysfunction. J Clin Prevent Cardiol 2013; 2(2): 91–94.

85.

Moens

Vrints

Claeys

. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol 2008; 294(5): H1971–H1977.

86.

Shookhoff

Gallicano

. A new perspective on neural tube defects: folic acid and microRNA misexpression. Genesis 2010; 48(5): 282–294.

87.

James

Pogribny

Pogribna

. Mechanisms of DNA damage, DNA hypomethylation, and tumor progression in the folate/methyl-deficient rat model of hepatocarcinogenesis. J Nutr 2003; 133: 3740S–3747S.

88.

Marsit

Eddy

Kelsey

. MicroRNA responses to cellular stress. Cancer Res 2006; 66(22): 10843–10848.

89.

Xie

Lim

Lodish

. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58(5): 1050–1057.

90.

Van Rooij

Purcell

Levin

. Developing microRNA therapeutic. Circ Res 2012; 110: 496–507.

91.

Obad

dos Santos

Petri

. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43: 371–378.

92.

Sheehan

Phan

. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 2001; 40: 4980–4989.

93.

Henry

Beattie

Yeh

. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol 2002; 2: 1657–1666.

94.

Van Rooij

Marshall

Olson

. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103: 919–928.

95.

Ebert

Neilson

Sharp

. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 2007; 4: 721–726.

96.

Lorenzen

Haller

Thum

. Biogenesis, mechanism of action and potential therapeutic utilities of miRNAs. Nat Rev Nephrol 2011; 7: 286–294.

MicroRNAs and cardiovascular medicine

Abstract

Keywords

Introduction

Synthesis of miRNAs

miRNAs and cardiac hypertrophy

Arrythmias and miRNAs

MI and miRNAs

Metabolic syndrome, cholesterol regulation and miRNAs

Vascular disease and miRNAs

Vascular proliferation

Inflammation

Angiogenesis

Heart failure and miRNAs

Preeclampsia and miRNAs

Endothelial dysfunction and miRNAs

miRNA-based therapies

Antagomirs

miRNA mimics

Conclusion

Footnotes

Acknowledgements

Declaration of conflicting interests

Funding

References